Additionally, a cancer-associated METTL11B mutant, D232N, has been identified that is at the predicted METTL11A interaction interface (Fig. 3h) and disrupts both the METTL11A–METTL11B interaction [80] and the ability of METTL11B to activate the methylation activity of METTL11A (unpublished data). Here, NTMT2 is linked to cancer.